A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2025-10-02		NCT05780034

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Accutar Biotechnology Inc	2

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Colorado Blood Cancer Institute	Denver	United States	178
Florida Cancer Specialists	Sarasota	United States	47
Oregon Health & Science University	Portland	United States	261
Swedish Cancer Institute	Seattle	United States	67
Tennessee Oncology	Nashville	United States	1
The Ohio State University - The James Cancer Hospital and Solove Research Institute	Columbus	United States	1
University Hospitals Cleveland Medical Center	Cleveland	United States	234
University of North Carolina	Chapel Hill	United States	101
University of Texas Southwestern Medical Center	Dallas	United States	249